Review of TA174; Rituximab for the first line treatment of chronic lymphocytic leukaemia, TA193; Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia

Proposal to move existing guidance to the static list

The planned consideration of a review of TA174 and TA193 is scheduled to take place within 6 months of the publication of the MO20927 trial. 

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

There is currently no substantive evidence that is likely to lead to a change in the existing recommendations made in TA174 and TA193.  Consideration was given to updating TA174 in a multiple technology appraisal with newer drugs for the same indication, but following consultation on the draft scopes, it has been decided that the appraisals for these newer drugs should proceed as single technology appraisals. 

Consequently we propose that TA174 and TA193 should move to the static list of technology appraisals.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.  Please see appendix A for a full list of the organisations we have contacted. 

January 2014